Literature DB >> 11683782

The molecular biology of von Willebrand disease.

S Keeney1, A M Cumming.   

Abstract

von Willebrand disease (VWD) is a common autosomally inherited bleeding disorder associated with mucosal or trauma-related bleeding in affected individuals. VWD results from either a quantitative or qualitative deficiency of von Willebrand factor (VWF)--a glycoprotein with essential roles in primary haemostasis and as a carrier of coagulation factor VIII (FVIII) in the circulation. In recent years the identification of mutations in the VWF gene in patients with VWD has improved our understanding of the structure and function of the VWF protein, and has illustrated the importance of specific regions of VWF for its interaction with other components of the vasculature. The underlying genetic lesions and associated molecular pathology have been identified in many cases of type 2A, type 2B, type 2M, type 2N and type 3 VWD. However in the most common variant, type 1 VWD, the causative molecular defect is unknown in the large majority of cases. In the absence of an understanding of the molecular pathology underlying type 1 VWD, precise diagnosis and classification of this common disorder remains problematic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683782     DOI: 10.1046/j.1365-2257.2001.00400.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  9 in total

Review 1.  Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere.

Authors:  Charles A Whittaker; Richard O Hynes
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

2.  Implications for collagen I chain registry from the structure of the collagen von Willebrand factor A3 domain complex.

Authors:  T Harma C Brondijk; Dominique Bihan; Richard W Farndale; Eric G Huizinga
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-21       Impact factor: 11.205

3.  Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.

Authors:  M L Bowman; F G Pluthero; A Tuttle; L Casey; L Li; H Christensen; K S Robinson; D Lillicrap; W H A Kahr; P James
Journal:  J Thromb Haemost       Date:  2017-06-06       Impact factor: 5.824

4.  Changes in thermodynamic stability of von Willebrand factor differentially affect the force-dependent binding to platelet GPIbalpha.

Authors:  Matthew Auton; Erik Sedlák; Jozef Marek; Tao Wu; Cheng Zhu; Miguel A Cruz
Journal:  Biophys J       Date:  2009-07-22       Impact factor: 4.033

5.  Platelet GPIbalpha, GPIV and vWF polymorphisms and fatal pre-hospital MI among middle-aged men.

Authors:  Minna Pellikka; Lassi Narhi; Markus Perola; Antti Penttila; Pekka J Karhunen; Jussi Mikkelsson
Journal:  J Thromb Thrombolysis       Date:  2007-07-11       Impact factor: 2.300

6.  Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.

Authors:  Alexander Tischer; Maria A Brehm; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Katelynn J Nelton; Rachel R Leger; Tobias Obser; Marina Martinez-Vargas; Steven T Whitten; Dong Chen; Rajiv K Pruthi; H Robert Bergen; Miguel A Cruz; Reinhard Schneppenheim; Matthew Auton
Journal:  J Mol Biol       Date:  2019-10-17       Impact factor: 5.469

7.  The venomous cocktail of the vampire snail Colubraria reticulata (Mollusca, Gastropoda).

Authors:  Maria Vittoria Modica; Fabrizio Lombardo; Paolo Franchini; Marco Oliverio
Journal:  BMC Genomics       Date:  2015-06-09       Impact factor: 3.969

8.  Antigenic Peptides Capable of Inducing Specific Antibodies for Detection of the Major Alterations Found in Type 2B Von Willebrand Disease.

Authors:  Marina de Oliveira Paro; Cyntia Silva Ferreira; Fernanda Silva Vieira; Marcos Aurélio de Santana; William Castro-Borges; Maria Sueli Silva Namen-Lopes; Sophie Yvette Leclercq; Cibele Velloso-Rodrigues; Milton Hércules Guerra de Andrade
Journal:  Int J Pept       Date:  2013-07-18

9.  The Chaperonin GroEL: A Versatile Tool for Applied Biotechnology Platforms.

Authors:  Pierce T O'Neil; Alexandra J Machen; Benjamin C Deatherage; Caleb Trecazzi; Alexander Tischer; Venkata R Machha; Matthew T Auton; Michael R Baldwin; Tommi A White; Mark T Fisher
Journal:  Front Mol Biosci       Date:  2018-05-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.